GB2412865A - Cough mixture comprising ipecacuanha and guaifenesin - Google Patents

Cough mixture comprising ipecacuanha and guaifenesin Download PDF

Info

Publication number
GB2412865A
GB2412865A GB0407954A GB0407954A GB2412865A GB 2412865 A GB2412865 A GB 2412865A GB 0407954 A GB0407954 A GB 0407954A GB 0407954 A GB0407954 A GB 0407954A GB 2412865 A GB2412865 A GB 2412865A
Authority
GB
United Kingdom
Prior art keywords
cough
cough mixture
mixture
ipecacuanha
mixture according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0407954A
Other versions
GB0407954D0 (en
Inventor
Atulkumar Sumanbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0407954A priority Critical patent/GB2412865A/en
Publication of GB0407954D0 publication Critical patent/GB0407954D0/en
Publication of GB2412865A publication Critical patent/GB2412865A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants

Abstract

A cough mixture comprising ipecacuanha tincture BP and guaifenesin Ph Eur. The mixture may further comprise menthol, liquorice extract and anise oil and may include pseudoephedrine hydrochloride. The mixture may include a sugar-free base syrup and a preservative. In particular the mixture is useful for a person needing to expectorate.

Description

24 1 2865
A COUGH MIXTURE
This invention relates to a cough mixture and, more especially, this invention relates to a cough mixture for a person requiring to expectorate, for example cough up phlegm.
There are various different types of coughs such for example as coughs which are known as dry coughs, coughs which are known as night time coughs, and coughs which require a person to expectorate. There are many different types of known cough mixtures for each type of cough.
Some of the known cough mixtures are more effective than others.
It is an aim of the present invention to provide a new cough mixture which is for a person requiring to expectorate and which is effective.
Accordingly, in one non-limiting embodiment of the present invention there is provided a cough mixture comprising ipecacuanha tincture BP and gualfenesin Ph Eur. The cough mixture of the present invention is especially advantageous for persons having coughs requiring them to expectorate.
The cough mixture may include menthol and/or liquorish extract and/or anise oil.
The cough mixture may comprise per 5ml of total solution: ipecacuanha tincture BP 0.1 ml gualfenesin Ph Eur 100mg menthol 2.5mg liquorish extract 0.25ml anise oil 0.05ml such a cough mixture is suitable for a person with a cough requiring the person to expectorate.
For a cough mixture for a person that requires an expectorant and also a decongestant, then the cough mixture may advantageously include pseudophedrine Hcl.
When the pseudophedrine Hcl is present, then the cough mixture may comprise: ipecacuanha tincture BP 0.1 ml gualfenesin Ph Eur 100mg menthol 2.5mg liquorish extract 0.25ml anise oil 0.05ml pseudophedrine Hcl 60mg The cough mixtures of the present invention may include at least one sugar-free base syrup.
Two typical sugar-free base syrups are as follows: 1. Malititol syrup Ploysorbate 80 Saccharin Sodium Citric Acid Monohydrate Strawberry Flavouring Purified Water 2. Maltitol Sorbitol Glycerol Cellulose Colouring The cough mixture may include at least one preservative.
The preservative may be included in the sugar-free base syrup.
Thus, for example, the above sugar-free base syrup No. 1 may include sodium methylhydroxybenzoate and sodium propylhydroxybenzoate, and the above sugar-free base syrup No. 2 may include ethyl parahydroxybenzoate, methyl parahydroxybenzoate and propyl parahyd roxybenzoate.
The cough mixture of the present invention is intended for adults and it is not normally intended for children.
Embodiments of the invention will now be described with reference to the accompanying non-limiting Examples.
EXAMPLE I
There was formulated a cough mixture which was for an adult with a cough requiring expectoration. The cough mixture comprised per 5ml of total solution: ipecacuanha tincture BP 0.1 ml gualfenesin Ph Eur 100mg menthol 2.5mg liquorish extract 0.25ml anise oil 0.05ml a sugar-free base syrup a preservative The adult was treated with the cough mixture for a period of days until the cough and the need for expectoration disappeared. During the treatment, the cough was kept under control to the benefit of the adult.
EXAMPLE II
There was formulated a cough mixture which was for an adult with a cough requiring expectoration and also decongestion. The cough mixture comprised per 5ml of total solution: ipecacuanha tincture BP 0.1 ml gualfenesin Ph Eur 100mg menthol 2.5mg liquorish extract 0.25ml anise oil 0.05ml pseudophedrine Hcl 60mg a sugar-free base syrup a preservative s The adult was treated with the cough mixture for a period of days until the cough and the need for expectoration and decongestion disappeared.
During the treatment, the cough was kept under control to the benefit of the adult.
In Examples I and 11 above, the sugar-free base syrup and the preservative may be combined as one of the following two formulations: 1. Malititol syrup Ploysorbate 80 Saccharin Sodium Citric Acid Monohydrate Sodium Methylhydroxybenzoate Sodium Propylhydroxybenzoate Strawberry Flavouring Purified Water 2. Maltitol Sorbitol Glycerol Cellulose Ethyl Parahydroxybenzoate Methyl Parahydroxybenzoate Propyl Parahydroxybenzoate Colouring A typical formula is as follows: Ascorbic Acid BP 29 Raspberry Flavour 1.5ml Mycasin 804-55 300ml Ethanol BP 25ml Benzoic Acid BP 0.69 Purified Water BP 175ml It is to be appreciated that the embodiments of the invention described above with reference to the accompanying Examples have been given by way of example only and that modifications may be effected. Thus, for example, because the cough mixtures of Examples I and 11 are intended for adults, they do not comprise flavourings. However, flavourings can be added if desired, as indicated by the strawberry flavouring in formulation No. 1 above. Any suitable and appropriate flavourings may be employed such for example as lemon or peppermint as alternatives to strawberry. f

Claims (10)

1. A cough mixture comprising ipecacuanha tincture BP and guaifenesin Ph Eur.
2. A cough mixture according to claim 1 and including menthol.
3. A cough mixture according to claim 1 or claim 2 and including liquorish extract.
A cough mixture according to any one of the preceding claims and including anise oil.
5. A cough mixture according to any one of the preceding claims and comprising per 5ml of total solution: ipecacuanha tincture BP 0.1 ml gualfenesin Ph Eur 100mg menthol 2.5mg liquorish extract 0.25ml anise oil 0.05ml
6. A cough mixture according to any one of the preceding claims and including pseudophedrine Hcl.
7. A cough mixture according to claim 6 and comprising per 5ml of total solution: ipecacuanha tincture BP 0.1 ml gualfenesin Ph Eur 100mg menthol 2.5mg liquorish extract 0.25ml anise oil 0.05ml pseudophedrine Hcl 60mg
8. A cough mixture according to any one of the preceding claims and including at least one sugar-free base syrup.
9. A cough mixture according to any one of the preceding claims and including at least one preservative.
10. A cough mixture substantially as herein described with reference to the accompanying Examples.
GB0407954A 2004-04-07 2004-04-07 Cough mixture comprising ipecacuanha and guaifenesin Withdrawn GB2412865A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0407954A GB2412865A (en) 2004-04-07 2004-04-07 Cough mixture comprising ipecacuanha and guaifenesin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0407954A GB2412865A (en) 2004-04-07 2004-04-07 Cough mixture comprising ipecacuanha and guaifenesin

Publications (2)

Publication Number Publication Date
GB0407954D0 GB0407954D0 (en) 2004-05-12
GB2412865A true GB2412865A (en) 2005-10-12

Family

ID=32320542

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0407954A Withdrawn GB2412865A (en) 2004-04-07 2004-04-07 Cough mixture comprising ipecacuanha and guaifenesin

Country Status (1)

Country Link
GB (1) GB2412865A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135559A1 (en) * 2011-03-31 2012-10-04 Mcneil-Ppc, Inc. Menthol liquids composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060258A (en) * 1964-12-05 1967-03-01 Sandoz Products Ltd Improvements in or relating to pharmaceutical pastilles
GB1144915A (en) * 1966-11-24 1969-03-12 Armour Pharma Improvements in or relating to pastille formulations
WO2003070154A2 (en) * 2002-02-20 2003-08-28 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060258A (en) * 1964-12-05 1967-03-01 Sandoz Products Ltd Improvements in or relating to pharmaceutical pastilles
GB1144915A (en) * 1966-11-24 1969-03-12 Armour Pharma Improvements in or relating to pastille formulations
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
WO2003070154A2 (en) * 2002-02-20 2003-08-28 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
http://www.union.com.sg/cough/coughdet.html *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135559A1 (en) * 2011-03-31 2012-10-04 Mcneil-Ppc, Inc. Menthol liquids composition
CN103476398A (en) * 2011-03-31 2013-12-25 麦克内尔-Ppc股份有限公司 Menthol liquids composition

Also Published As

Publication number Publication date
GB0407954D0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
TW349870B (en) An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
BR0308927A (en) Pleasant Chewable Tablet
EP0950402A3 (en) Chewable pharmaceutical composition with gelatin matrix
CR7264A (en) SUCRALOSE FORMULATIONS TO HIDDEN DISAGULABLE FLAVORS
US6417206B1 (en) Antitussive/antihist aminic/decongestant compositions
US5055461A (en) Anesthetic oral compositions and methods of use
CA2470464A1 (en) Use of heliopsis longipes extract in oral compositions
NO20015931L (en) Pharmaceutical formulations and methods comprising intranasal morphine
SG152257A1 (en) Topical preparation containing ambroxol
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
US6462094B1 (en) Decongestant/expectorant compositions
ATE213626T1 (en) SOLID THERAPEUTIC OR HYGIENIC MUCOADHESIVE COMPOSITION FOR ADMINISTRATION BY APPLICATION TO THE ORAL MUCOSA OR NASAL MUCOSA
HUP0204550A2 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation and process for its preparation
US5100898A (en) Antitussive liquid compositions containing dyclonine
WO2015144255A1 (en) Oral solution comprising atomoxetine hydrochloride
US4892877A (en) Antitussive liquid compositions containing phenol
HUP0201307A2 (en) Taste masked compositions
US5932589A (en) Antitussive composition containing dextromethorphan and benzydamine
IT1295408B1 (en) ASSOCIATION OF L-CARNITINE AND ALCANOYL L-CARNITINE FOR THE TREATMENT OF ALCOHOLISM
Scott et al. Effects of amitriptyline and zimelidine in combination with ethanol
GB2412865A (en) Cough mixture comprising ipecacuanha and guaifenesin
GB2424185A (en) Cough mixture comprising codeine linctus and guaifenesin
EP1694295B1 (en) Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability
PT1312355E (en) NON-EFFERVESCENT PHARMACEUTICAL COMPOSITIONS IN WATER COMPREHENDING ANTI-INFLAMMATORY DRUGS NAO-STEROIDES
US4931473A (en) Anesthetic oral compositions

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)